Achillion Pharmaceuticals
Company Overview
Achillion Pharmaceuticals was a clinical-stage biopharmaceutical company that focused on developing treatments for complement-mediated diseases. The company was acquired by Alexion Pharmaceuticals in January 2020 for $930 million. Later in December 2020, Alexion itself was acquired by AstraZeneca.
Since the original company ACHN no longer exists as a separate entity, this report cannot provide a meaningful halal compliance analysis of the original ticker. Investors interested in this space should instead analyze AstraZeneca (AZN), which now owns the assets and operations of both Achillion and Alexion Pharmaceuticals.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Achillion Pharmaceuticals's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.